TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
TELA Bio, Inc. (Nasdaq: TELA), a Delaware corporation, filed this Current Report on Form 8-K on March 24, 2026. The filing announces the release of financial results for the fourth quarter and full fiscal year ended December 31, 2025, and includes an updated corporate investor presentation.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) and corporate slide deck (Exhibit 99.2) referenced in the report but are not detailed in the 8-K body text.
Material Changes
No specific material changes in financial condition or operations are quantified in this filing. The document serves as a notification that the Company has issued a press release regarding its Q4 and full-year 2025 results and has updated its investor presentation materials.
Guidance, Outlook, and Risks
The Company updated its corporate slide deck for use in investor meetings, which may contain forward-looking statements or updated outlooks. The filing explicitly states that the information furnished under Item 2.02 and Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2025 financial results.
- Examine Exhibit 99.2 (Corporate Slide Deck) for updated operational milestones and guidance.
- Verify the Company's cash runway and burn rate, as these are not disclosed in the 8-K text.
- Confirm any new clinical trial data or regulatory updates mentioned in the attached exhibits.